Adenocarcinoma of Unknown Primary Diagnosis and Management

Introduction to Adenocarcinoma of Unknown Primary

The National Comprehensive Cancer Network recommends that a cancer of unknown primary (CUP) with an immunoprofile of pankeratin+/CK7+/CK20-/TTF1-/CDX2-/PSA- requires immediate additional immunohistochemical workup and clinical correlation to identify the primary site, as this pattern is consistent with multiple possible origins including pancreaticobiliary, breast, ovarian, endometrial, gastric, or TTF1-negative lung adenocarcinoma 1, 2.

The CK7+/CK20- pattern narrows the differential to lung, breast, thyroid, pancreatic, ovarian, endometrioid, gastric, urothelial, or endocervical carcinomas, according to the National Comprehensive Cancer Network 3, 4.

Pancreaticobiliary adenocarcinoma is a leading consideration with this profile (CK7+/CK20-/TTF1-/CDX2-), particularly if the patient has liver metastases, as suggested by the Annals of Oncology 1, 2.
Breast carcinoma must be excluded, especially in female patients, as 98% of breast cancers are CK7+ and 92% are CK20-, according to the Journal of the National Comprehensive Cancer Network 4.

For female patients, GATA3 must be performed immediately to screen for breast cancer, as recommended by the Annals of Oncology 1, 2, 5.
SOX10 should be added to evaluate for triple-negative breast cancer, according to the Annals of Oncology 1, 2.
ER/PR (estrogen receptor/progesterone receptor) are essential breast markers with high specificity, as stated by the Journal of the National Comprehensive Cancer Network 6.

CT scans of chest, abdomen, and pelvis are mandatory baseline imaging for all CUP patients, as recommended by the Annals of Oncology 1, 8.
Mammography is required for all female patients given the high likelihood of breast primary, according to the Annals of Oncology 8.

Empiric platinum-based chemotherapy (paclitaxel 200 mg/m² + carboplatin AUC=6 every 3 weeks) is the standard treatment for adenocarcinoma CUP with unfavorable features, as stated by the Journal of the National Comprehensive Cancer Network 6.
Site-specific therapy should be administered if additional IHC and clinical workup identify a likely primary, such as breast origin, pancreaticobiliary origin, or ovarian origin, according to the Journal of the National Comprehensive Cancer Network 6.

Median survival for adenocarcinoma CUP with unfavorable features (multiple organ metastases) is approximately 3 months without treatment, with 1-year survival <20%, as reported by the Annals of Oncology 1, 2.
Extranodal disease (liver, lung, bone metastases) carries significantly worse prognosis than lymph node-only disease, according to the Annals of Oncology 1, 2.
Performance status is the most important factor determining treatment candidacy—only patients with PS 0-2 should receive chemotherapy, as stated by the Journal of the National Comprehensive Cancer Network 6.